Advertisement

Topics

Eli Lilly & Co. Says Its Migraine Drug Met Primary Endpoint In Late-stage Trial

09:30 EDT 4 Aug 2017 | Topix

Eli Lilly & Co. said early Friday that its migraine drug lasmiditan met its primary endpoint and a key secondary endpoint in a late-stage clinical trial.

Original Article: Eli Lilly & Co. Says Its Migraine Drug Met Primary Endpoint In Late-stage Trial

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly & Co. Says Its Migraine Drug Met Primary Endpoint In Late-stage Trial"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...